360° SearchNetwork Hot Spots Trends Time Series

Advanced Search Options >>

Zerenex

Type: Product

Name: Zerenex

First reported Jun 11 2013 - Updated Jun 11 2013 - 2 reports

ACADIA Pharmaceuticals Inc

5 best-performing biotech stocks of 2013

The five best-performing biotech and drug stocks as we near the midway point in 2013: 1. Clovis Oncology (CLVS) Clovis had "only" doubled in value through May 31 when the stock really took off following the presentation of data from a phase I study of ... [Published MSN Money - Jun 11 2013]

Entities: ACADIA Pharmaceuticals Inc, Biotechnology, Keryx Biopharmaceuticals Inc, antineoplastic, Zerenex

First reported Jun 06 2013 - Updated Jun 06 2013 - 1 reports

Keryx Biopharmaceuticals Presents Zerenex Phase 3 Data

Keryx Biopharmaceuticals, Inc. announced the presentation of updated efficacy and safety data from the Phase 3 long-term clinical trial of Zerenex (ferric citrate), the Company's ferric iron-based phosphate binder drug candidate for the treatment of elevated ... [Published Individual.com - Jun 06 2013]

Entities: Zerenex, Keryx Biopharmaceuticals Inc, Phase III, Serum

First reported Jun 05 2013 - Updated Jun 05 2013 - 1 reports

KERYX BIOPHARMACEUTICALS INC FILES (8-K) Disclosing Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits

Item 5.02. Departure of Directors or Certain Officers; Election of Directors;Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.(e) On May 29, 2013, Keryx's Compensation Committee approved the grant of incentive bonuses to ... [Published Pharmacy Choice - Jun 05 2013]

Entities: Keryx Biopharmaceuticals Inc, 8-k, Zerenex, Citrate

First reported Jun 04 2013 - Updated Jun 04 2013 - 1 reports

Solid Showing At WCN Conference For Keryx: Catalysts Still To Come

By Jake KingKeryx Biopharmaceuticals (KERX) presented additional details from its pivotal Phase III study for Zerenex Monday at the World Congress of Nephrology (WVN) meeting during a lunch presentation. Some early profit taking this morning took the ... [Published Seeking Alpha - Jun 04 2013]

Entities: Chronic Kidney Disease, Keryx Biopharmaceuticals Inc, Catalyst, Zerenex

First reported Jun 03 2013 - Updated Jun 03 2013 - 2 reports

Keryx Biopharma Says Zerenex Met Primary, Secondary Endpoint. . .

Keryx Biopharma Says Zerenex Met Primary, Secondary EndpointsPaul QuintaroBenzingaKeryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced the presentation of updated efficacy and safety datafrom the Phase 3 long-term clinical trial of Zerenex (ferric ... [Published Equities.com - Jun 03 2013]

Entities: Zerenex, Serum, Active Control Technology

First reported Jun 03 2013 - Updated Jun 03 2013 - 3 reports

Keryx Biopharmaceuticals Inc

Keryx (KERX) Will Present Updated Zerenex Phase 3 Data

Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced the presentation of updated efficacy and safety data from the Phase 3 long-term clinical trial of Zerenex (ferric citrate), the Company's ferric iron-based phosphate binder drug candidate for the ... [Published Street Insider - Jun 03 2013]

Entities: Zerenex, Keryx Biopharmaceuticals Inc, Phase III, Serum

First reported May 30 2013 - Updated May 30 2013 - 1 reports

Keryx: Attractive In Front Of Catalyst-Rich Second Half

By Jake KingShares of Keryx Biopharmaceuticals (KERX) continue to trade within a tight range, but with several catalyzing events approaching, we believe the stock is ready to break out. In particular, clinical evidence for a second, larger indication ... [Published Seeking Alpha - May 30 2013]

Entities: Keryx Biopharmaceuticals Inc, Zerenex, Nephrology, Feraheme, epoetin alfa

First reported May 24 2013 - Updated May 24 2013 - 2 reports

A Review Of Upcoming Catalysts For Kidney Disease Biotech Players In 2013

Home » Blogs » With a potential U.S. market for Chronic Kidney Disease (CKD) and End Stage Renal Disease (ESRD) patients of almost $1bb, based on 5mm CKD patients above age 65, of whom ~50% are in stage 3-5, there is ample opportunity for a few under-appreciated ... [Published BioPortfolio - May 24 2013]

Entities: Kidney Disease, Biotechnology, Chronic Kidney Disease, Keryx Biopharmaceuticals Inc

First reported May 21 2013 - Updated May 21 2013 - 1 reports

Why Keryx is Lagging But Acadia is Zooming (Hint: It's About NCE)

BOSTON (TheStreet) -- Something is ailing Keryx Biopharmaceuticals (KERX)The chart above explains what I mean. Keryx shares (the blue line) are down almost 13% since the start of February while the Nasdaq Biotechnology Index (NBI in orange) is up more ... [Published TheStreet.com - May 21 2013]

Entities: Keryx Biopharmaceuticals Inc, ACADIA Pharmaceuticals Inc, Zerenex, Patent, Biotechnology

First reported Apr 22 2013 - Updated Apr 22 2013 - 1 reports

Keryx, Zerenex, And IP Protection: A PropThink Conference Call

ByPropThink: On April 11, PropThink hosted an Interview and Q&A (via conference call) for PropThink subscribers with Dr. Scott Chambers, a leading patent attorney and former staff at the USPTO. The conference call centered around Keryx Biopharmaceuticals ... [Published Healthcare Sector and Stocks Analysis from Seek ... - Apr 22 2013]

Entities: Zerenex, Keryx Biopharmaceuticals Inc, Intellectual Property, Patent

First reported Apr 08 2013 - Updated Apr 09 2013 - 1 reports

What You Need To Know About Keryx And Zerenex's IP

ByPropThink: By Jake King For Keryx Biopharmaceutical's ( KERX ), a major debate on the strength of Zerenex's IP estate has been ongoing since the company reported impressive Phase III results for the phosphate binder in January. Skepticism on the ... [Published Healthcare Sector and Stocks Analysis from Seek ... - Apr 08 2013]

Entities: Keryx Biopharmaceuticals Inc, Zerenex, Phosphate, Phase III, Jake King

First reported Mar 13 2013 - Updated Mar 13 2013 - 1 reports

Zerenex Patent Protection Is Key For Keryx Upside, But EU Exclusivity Provides A Base

ByPropThink: By Jake King Keryx Biopharmaceuticals' ( KERX ) CEO, Ron Bentsur, spent much of the company's 4Q/YE12 earnings conference call reviewing patents, pending patents, and potential exclusivity designations for Zerenex, the company's late-stage ... [Published Healthcare Sector and Stocks Analysis from Seek ... - Mar 13 2013]

Entities: Zerenex, Keryx Biopharmaceuticals Inc, Patent

Quotes

...Collaborative Study Group, and Study Chair of the Zerenex PhasePhase 3 registration program, presented the updated dataset from the study entitled "A 58-Week Safety and Efficacy Trial of Ferric Citrate in Patients With ESRD on Dialysis" in a symposium held in Hong Kong, during the 2013 World Congress of Nephrology

Keryx Biopharmaceuticals Presents Zerenex Phase 3 Data [Published Individual.com - Jun 06 2013]

...as well as those who haven't taken crizotinib," said lead investigator Alice T Shaw, MD, PhD, Massachusetts General Hospital Cancer Center, Boston. "LDK378 may become another standard targeted therapy for these ALK-positive patients."

Novartis Says Breakthrough Therapy LDK378 Shows Response; Nektar Announces Positive Preclinical D ... [Published BioMedReports - Jun 04 2013]

..."Mr. Bentsuradded, "We look forward to the presentations of additional data from the studyat upcoming medical conferences."

Keryx Biopharma Says Zerenex Met Primary, Secondary Endpoint. . . [Published Equities.com - Jun 03 2013]

More From BioPortfolio on "A Review Of Upcoming Catalysts For Kidney Disease Biotech Players In 2013"

A Review Of Upcoming Catalysts For Kidney Disease Biotech Players In 2013 [Published BioPortfolio - May 24 2013]

More Content

sort by: Date \| Relevance
5 best-performing biotech stocks of 2013 [Published MSN Money - Jun 11 2013]
PropThink Biotech Stocks with Big Upside Potential [Published 24/7 Wall St - Jun 11 2013]
Five Best-Performing Biotech Stocks of 2013 (So... [Published TheStreet.com - Jun 11 2013]
Keryx Biopharmaceuticals Presents Zerenex Phase... [Published Individual.com - Jun 06 2013]
KERYX BIOPHARMACEUTICALS INC FILES (8-K) Disclo... [Published Pharmacy Choice - Jun 05 2013]
Solid Showing At WCN Conference For Keryx: Cata... [Published Seeking Alpha - Jun 04 2013]
Novartis Says Breakthrough Therapy LDK378 Shows... [Published BioMedReports - Jun 04 2013]
Keryx Biopharma Says Zerenex Met Primary, Secon... [Published Equities.com - Jun 03 2013]
Keryx (KERX) Will Present Updated Zerenex Phase... [Published Street Insider - Jun 03 2013]
KERYX BIOPHARMACEUTICALS : Keryx Biopharmaceuti... [Published 4 Traders - Jun 03 2013]
Keryx Biopharma Says Zerenex Met Primary, Secon... [Published Benzinga.com - Jun 03 2013]
Keryx announces positive Zerenex Phase 3 data [Published Yahoo! Finance - Jun 03 2013]
Keryx Biopharmaceuticals, Inc. Announces Zerene... [Published PR Newswire: General Business - Jun 03 2013]
Keryx: Attractive In Front Of Catalyst-Rich Sec... [Published Seeking Alpha - May 30 2013]
A Review Of Upcoming Catalysts For Kidney Disea... [Published BioPortfolio - May 24 2013]
A Review Of Upcoming Catalysts For Kidney Disea... [Published Seeking Alpha - May 24 2013]
Why Keryx is Lagging But Acadia is Zooming (Hin... [Published TheStreet.com - May 21 2013]
Keryx, Zerenex, And IP Protection: A PropThink ... [Published Healthcare Sector and Stocks Analysis from Seek ... - Apr 22 2013]
What You Need To Know About Keryx And Zerenex's IP [Published Healthcare Sector and Stocks Analysis from Seek ... - Apr 08 2013]
The Validity And Risk Of Keryx Biopharmaceuticals [Published Healthcare Sector and Stocks Analysis from Seek ... - Mar 20 2013]
Zerenex Patent Protection Is Key For Keryx Upsi... [Published Healthcare Sector and Stocks Analysis from Seek ... - Mar 13 2013]
Keryx Biopharmaceuticals' CEO Presents at Citi ... [Published Healthcare Sector and Stocks Analysis from Seek ... - Feb 28 2013]
Financings of the Fortnight Sees Signs That Poi... [Published The IN VIVO Blog - Feb 08 2013]
A Closer Look At Keryx Biopharmaceuticals' Phas... [Published Healthcare Sector and Stocks Analysis from Seek ... - Feb 04 2013]
Research Report Misses The Mark - A Second Chan... [Published Healthcare Sector and Stocks Analysis from Seek ... - Feb 04 2013]
4 Healthcare Stock Stories for Thursday Wellness [Published Wall St. Cheat Sheet - Jan 31 2013]
4 Healthcare Stock Stories for Wednesday Wellness [Published Wall St. Cheat Sheet - Jan 30 2013]
Keryx: Take The Money And Run? [Published Healthcare Sector and Stocks Analysis from Seek ... - Jan 30 2013]
Discover Weakness Deemed Unwarranted and 4 Stoc... [Published Wall St. Cheat Sheet - Jan 29 2013]
Keryx Biopharmaceuticals' CEO Presents at Top-L... [Published Healthcare Sector and Stocks Analysis from Seek ... - Jan 28 2013]

Blogs

sort by: Date \| Relevance
Financings of the Fortnight Sees Signs That Poi... [Published The IN VIVO Blog - Feb 08 2013] Oh, the siren song. The new year arrives, the buzz and handshakes at the JPMorgan conference get everyone hopped up, and a scramble of biotech IPO activity lights up the wires. In 2012 it was Verastem, Adocia, Cempra and Chemocentryx all going through ...
4 Healthcare Stock Stories for Thursday Wellness [Published Wall St. Cheat Sheet - Jan 31 2013] Johnson & Johnson ( NYSE:JNJ ): Current price $74.08 The European Commission has sent antitrust objections to Novartis ( NYSE:NVS ) and Johnson & Johnson in regards to a pay-for-delay arrangement that might have deterred sales of generic versions ...
4 Healthcare Stock Stories for Wednesday Wellness [Published Wall St. Cheat Sheet - Jan 30 2013] Isis Pharmaceuticals ( NASDAQ:ISIS ): Current price $14.69 Kynamro, a drug developed by Isis, was approved by the FDA Tuesday and will be marketed by Sanofi’s Genzyme division. The medication treats a rare inherited disorder that causes extremely ...
Discover Weakness Deemed Unwarranted and 4 Stoc... [Published Wall St. Cheat Sheet - Jan 29 2013] Keryx Biopharmaceuticals Inc. ( NASDAQ:KERX ): Current Price: $8.10 The company’s price target has been increased to $15 by Brean Capital due to positive Ph III Zerenex data. The stock has a Buy rating. Markets are at 5-year highs! Discover the ...
Japan Tobacco files NDA for Ferric Citrate in J... [Published PBR - News - Jan 08 2013] Japan Tobacco (JT), Keryx Biopharmaceuticals' Japanese partner, has filed a new drug application (NDA) for the marketing approval of Ferric Citrate (Zerenex) in Japan for the treatment of hyperphosphatemia in chronic kidney disease (CKD) patients. ...

Press Releases

sort by: Date \| Relevance
Keryx Biopharmaceuticals, Inc. Announces Zerene... [Published PR Newswire: General Business - Jun 03 2013]
Keryx Biopharmaceuticals Announces Zerenex™ (fe... [Published PR Newswire: Health - Jan 28 2013]
Keryx Biopharmaceuticals to Hold Conference Cal... [Published PR Newswire: Health - Jan 27 2013]
U.S. Nephrologists Report a Decreasing Trend in... [Published PR Newswire: Health - Jan 14 2013]